Research Article

The Implementation of a Geriatric Patients Blood Management Program based on CBA to Monitor Hemoglobin Level in Nursing Homes

Vanalli M*

Nursing Home Santa Chiara, University of Milano-Bicocca, Italy

*Corresponding author: Vanalli M, Nursing Home Santa Chiara, University of Milano-Bicocca, Italy

Abstract

Background: In line with Resolution WHO63.12 of 21/05/2010 from the World Health Organization, the Italian National Blood Center has promoted an initiative encapsulated by the term Patient Blood Management (PBM). Aim of this study is to examine the relationships among the prevalence of genera-age-associated risk factors of anaemia and hemoglobin level in geriatric patients with cognitive decline through CBA SIPCAR plus.

Method: The CBA database has been developed by a dedicated working group using Delphi process and PBM. It contains records on patient characteristics, and one set of biomarker laboratory.

Results: Between 2014 and 2015, 283 geriatric patients were enrolled at three Italian elderly nursing homes.

Among these patients, 14% were men and 86% were women (mean age 79 years) and the overall prevalence of anemia was 55.9%; 32.6% of the geriatric patients were at risk of malnutrition and 11.5% were malnourished. Multivariate analysis determined that comorbidity was highly associated with malnutrition risk measured by Malnutrition Universal Screening Tool≥2, cognitive decline measured by Mini-mental State Examination≤19, functional independence in two or more basic activities of daily living, Hgb level of 69 g/L (p=0.01) and Hgb level of 100 g/L (p=0.02). Two variables were significantly associated with an increase of the transfusion threshold above 90 g/L: the poor tolerance of anemia (p=0.001) and clinical risk situations (p=0.03).

Conclusion: The appropriateness of results could be useful to better describe the role of PBM with CBA and biomarkers recorded in geriatric practice, transfusion thresholds, target hemoglobin levels after transfusion.

Keywords: Anemia; Patient blood management; CBA outcome set; Cumulative illness rating scale; Nursing home

Abbreviations

WHO: World Health Organization; PBM: Patient Blood Management; CBA: Social Health Folder; CIRS-Cumulative Illness Rating Scale; CRS: Cricthon Rating Scale; MUST: Malnutrition Universal Screening Tool; MMSE: Mini-mental State Examination; CI: Confidence interval; CrCl: Creatinine Clearance; CGA: Comprehensive geriatric assessment; MLF: Multidimensional loss of function

Introduction

In line with Resolution WHA63.12 of 21/05/2010 from the World Health Organization, the Italian National Blood Centerhas promoted an initiative aimed at systematizing innovative and more effective methods and instruments for ensuring appropriate organisational and clinical management of blood use [1]. This initiative is a ground-breaking multiprofessional, multidisciplinary and multimodal project encapsulated by the term Patient Blood Management (PBM) and Geriatric Anemia.

Anemia in the elderly (defined as people aged > 65 years) is common and increasing as the population ages. In older patients, anemia of any degree contributes significantly to morbidity and mortality and has a significant effect on the quality of life. Despite its clinical importance, anemia in the elderly is under-recognized and evidence-based guidelines on its management are lacking [2].

Causes of anemia in the elderly are divided into three broad groups: nutritional deficiency, Anemia of Chronic Disease (ACD) and Unexplained Anemia (UA). These groups are not, however, mutually exclusive. In any given patient, several causes may co-exist and may each contribute independently to the anemia.

Other causes like Cancer or hematological malignancy related anemia were investigated for renal failure and/or inflammation (myelodysplastic syndromes, chronic leukemia or lymphoma and sarcopenia). Both types may cause anemia, mainly via erythropoiesis inhibition by cytokines, although the mechanisms of inflammatory anemia are incompletely elucidated. As a result, protracted elevation of Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α in the

plasma of elderly patients after exposure to inflammatory stimuli can be seen. This may be a common mechanism for the production of anemia in chronic illness unique to elderly patients [3].

Another approach is based on the definition of Hb concentrations that are optimal for the clinical outcome of elderly subjects. Based on the distribution of Hb levels [4].

Anemia of the elderly represents a challenge and a burden for the individual, the community and health care providers. All healthcare providers should be aware that anemia impacts a significant group within our societies. It is an entity that lies within our ability to diagnose and treat with PBM.

PBM is a holistic approach to the management of blood as a resource for each, single patient; it is a multimodal strategy that is implemented through the use of a set of techniques that can be applied in individual cases [5]. Indeed, the overall outcome resulting from the implementation of PBM cannot be fully appreciated and explained simply by summing the effects of the single strategies and techniques used, since these can only produce the expected optimal outcome if used in combination [6]. PBM is, therefore, a patient-centered and multidisciplinary project what involved Hematology, Geriatric, Physiotherapist, Nurse or just primary care. It is, also, a multimodal approach to the optimal management of anaemia and haemostasis, to limiting allogeneic transfusion needs, and to appropriate use of blood components and, when relevant, plasmaderived medicinal products [7].

The concept of PBM is not centered on a specific pathology or procedure, nor on a specific discipline or sector of medicine, but is aimed at managing a resource, "the patient's blood", shifting attention from the blood component to the patient who, therefore, acquires a central and preeminent role [8].

PBM combines the dual purposes of improving the outcomes of patients and reducing costs, being based on the patient rather than on allogeneic blood as the resource. For this reason, PBM goes beyond the concept of appropriate use of blood components and plasma-derived medicinal products, since its purpose is to avoid or significantly reduce their use, managing, in good time, all the modifiable risk factors that can lead to a transfusion being required [9].

These aims can be achieved through the so-called "three pillars of PBM", which are crucial for making the paradigmatic shift that characterizes the innovative, patient-centered approach:

(i) optimizing the patient's erythropoiesis;

(ii) minimizing bleeding; and

(iii) optimizing and exploiting an individual's physiological reserve to tolerate anaemia. Each of these three key points is a strategic response to clinical circumstances that can cause adverse outcomes and necessitate the use of allogeneic transfusion therapy, namely anaemia, blood loss and hypoxia, respectively [10].

(iv) PBM is, therefore, intended to guarantee all patients a series of personalized program, based on clinical requirements and the characteristics of the patients themselves, with the dual purposes of using allogeneic transfusion support appropriately and reducing the need for this resource. For this reason, PBM requires multidisciplinary and multimodal strategies to systematically identify, evaluate and manage anaemia (boosting, if necessary, individual physiological reserves) and to avoid or minimize blood losses. It seems necessary to produce specific national standards [11].

Aim of this study is to examine the relationships among the prevalence of genera-age-associated risk factors of anaemia and hemoglobin level in geriatric patients with cognitive decline through CBA SIPCARplus (medical records).

Materials

The CBA database has been developed by a dedicated working group using Delphi process and PBM. It contains records on patient characteristics called health-assessment-delivery-warnings-analysis area, and one set of biomarker laboratory data identified in several variables (the hemoglobin level, iron, ferritin, transferrin saturation, folate, vitamin B12, C-reactive protein, thyroid-stimulating hormone-TSH, albumin, and haptoglobin). It was categorized into normal and abnormal values according to standard laboratory norms.

The three pillars of the PBM with CBA are:

1) Optimization of erythropoiesis: detect anaemia; identify and treat its underlying causes; re-evaluate the patient, if necessary; treat iron deficiency and iron-deficiency anaemia, anaemia of chronic disease and functional iron deficiencies, so-called ironrestricted erythropoiesis; treat deficiencies of other haematinics.

2) Minimize blood losses: identify and manage bleeding risk, minimize iatrogenic bleeding, plan the procedure carefully and prepare well in very selected cases.

3) Optimization of the tolerance of anaemia: assess and optimize the patient's physiological reserve to tolerate anaemia and risk factors; compare estimated blood loss with the individual patient's tolerable blood loss; formulate a personalized blood management programthat includes patient specific blood-conservation techniques; adopt restrictive blood transfusion thresholds.

Descriptive and inferential statistics were applied to describe and compare patients' demographic and epidemiological characteristics in Nursing Home. The IBM SPSS version 21 statistical software was used to perform data analyses. The data analysis was concluded in January 2014.

Methods

Researchers responsible for recruitment from three nursing homes informed management and potential participants about the study. Inclusion criteria were as follows: age, availability of a venous blood sample result including Hemoglobin (Hb) concentration collected during the current nursing home stay, possibility of verbal communication with the patient or a proxy, and informed consent to participate by the patient or legal guardian. Exclusion criteria were as follows: non-correctable visual or hearing impairment, severe pain, sedation, or clinical depression. Blood samples were taken for laboratory biomarker assays of Hb level, iron, ferritin, transferrin saturation, folate, vitamin B12, C-reactive protein, TSH, albumin, and haptoglobin.

The Comprehensive Geriatric Assessment (CGA) for this study consisted of six tools and their ranking methodologies to evaluate

Figure 1: CBA and their respective point scores.

the following functional domains: cognition, mobility, transfer skills, competence in performing Basic Activities of Daily Living (BADLs), and swallowing ability [12]. The Barthel Index (BI) assesses BADL functionality using a rating scale from 0 (totally dependent) to 100 (maximal independence). An abnormal outcome was defined as 90 points or less [13]. The Mini Mental State Examination (MMSE) measures the global cognitive state with a rating ranging from 0 (severe cognitive impairment) to 30 (normal cognitive function) [14]. Results of 27 points or less were considered abnormal. The Clock-Drawing Test (CDT) covers cognitive domains incompletely tested for by the MMSE, such as executive function and spatial visualization skills. It uses a scale from 1 (perfect) to 6 (no reasonable representation of a clock), with a result of 3 or higher rated as abnormal. The Timed Up and Go (TUG) test was used to assess mobility status. For methodical reasons, it uses five ranks according to the time needed to finish the test: ≤15 s, 1; >15 to ≤25 s, 2; >25 to ≤35 s, 3; >35 s, 4; and TUG test not realizable 5. Results of 3 or higher were considered abnormal. The Esslinger Transfer Scale (ETS) refers to the degree of independence while changing position in bed and transferring oneself from bed to chair, and it ranges from 0 (no assistance needed) to 4 (more than one professional assistant required). Ranks from 2 upwards were regarded as a functional limitation. The Daniels test was utilized to detect dysphagia and was rated abnormal (positive) or not. Multidimensional loss of function (MLF) as an aggregated outcome was diagnosed when three or more CGA tests showed an abnormal result [15].

In order to adjust for possible confounding factors in the relationship between anemia and MLF, this study collected information concerning 12 major comorbidities directly from patients and by studying their medical histories. Renal and thyroid functions were assessed on the basis of laboratory results: serum creatinine concentration with a standard of 0.5–0.9 mg/dL in women and 0.5–1.1 mg/dL in men, and TSH with a standard of 0.27 and 4.20 µIU/mL, respectively). Multimorbidity was defined as the non-specific presence of more than one major disease [16].

This study was approved by the Internal Review Board of the university hospital, Bergamo. Informed consent was procured, and the protection and confidentiality of data was guaranteed according to applicable privacy laws.

Results

Epidemiological studies consistently show an increase in the prevalence of anemia with advancing age, despite differences across studies in patient characteristics such as age and comorbidities [17].

Perhaps of greater significance, anemia has been shownto impact mortality in elderly patients with other co-morbid conditions. For example, Esekowitz and colagueshave shown an increase in mortality in elderly patients with congestive heart failure as compared with their non-anemic cohorts [18].

Improvement in hemoglobin levels can also lead to improvements

Figure 2: CBA and MUST point scores.

in end-organ function. Hayashi and colleagues have shown left ventricular function improves in chronic renal failure patients treated with erythropoietin. These data begin to address the important question of the relative roles of the anemia and the co-morbid condition in the excess morbidity and mortality experienced by the anemic elderly [19].

In this study 283 geriatric patients at three Italian nursing homes for the elderly were enrolled during 2014 and 2015. The mean age of enrolled patients was 79 years, with 14% male and 86% female. The overall prevalence of anemia was 55.9%. 32.6% of patients were at risk for malnutrition and 11.5% were malnourished. Comorbidities were weighted with the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) ≥4 [20] (Figure 1) The mean total CIRS-G score was 9±3.7 and the mean composite CIRS-G score was 3.7±1.5. The mean Creatinine Clearance (CrCl) was 40.9±16.5 mL/min (Normal values was: 56 to 131 mL/min). The mean Hb level was 122 g/L. The Hb level was <120 g/L in 110 (61.1%) patients and ≥120 g/L in 173 (38.9%) patients. In the group with severe anemia, the mean Hb level was 105±11 g/L [21].

Anemia was multifactorial in most patients: the mean number of potential causes per patient was 1.85±1, and 65.4% of patients had two to four concomitant causes [22,23]. Anemia prevalence was 2.12-fold higher in patients at risk for malnutrition that the malnourished groups. When the study compared age, sex, CrCl, and comorbidity scores in the groups with and without anemia, the total CIRS-G score was the only variable significantly and independently associated with anemia (p<0.001) [24]. The total CIRS-G score was also the only variable significantly associated with the Hb level in the multivariate analysis (p<0.001). Multivariate analysis determined that comorbidity was highly associated with malnutrition risk as measured by the Malnutrition Universal Screening Tool ≥2 (Figure 2); cognitive decline as measured by the MMSE ≤19; functional dependence in two or more basic activities of daily living; Hb level of 69 g/L (p=0.01); and

Hb level of 100 g/L (p=0.02) (Table 1).

Overall, 61% of patients presented with three or more abnormal results in the six tests of the CGA and were thus diagnosed with MLF. Logistic regression identified a significant association of both anemia and low Hb concentrations with abnormal outcomes in five tests of the CGA and therefore with functional deficits like mobility limitation, impaired cognition, and dysphagia. Furthermore, being anemic increased the odds of MLF more than fourfold [25]. The significance of this relationship persisted after adjustment for various major comorbidities. Given the association of anemia with MLF, Hb level might serve as a useful geriatric screening marker to identify frail older people at risk for adverse outcomes; such a screening should contain indicators of functional deterioration [26].

This study also evaluated anemia treatment to gain insights into Hb threshold for transfusion [27].

The mean hemoglobin level before red blood cell transfusion was 84.5±9.4 g/L. There was a significant inverse relationship between the baseline Hb and the Hb response to treatment (p=0.007) [28]. Hb loss after treatment decreased from 38 (29-49) g/L at baseline to 31 (26-40) g/L after algorithm implementation (p<0.001). The mean number of red blood cell units prescribed for each transfusion was 1.88±0.55, with the only predictive factor being the hemoglobin level (p<0.001). Two variables were significantly associated with an increase of the

Table 1: Multivariate Analyses of Geriatric test score, comorbidity score and biomarkers laboratory.

Comorbidity	MUST ≥2 p	MMSE ≤19 p	Barthel Index ≤50 p
Hb>6,9 g/dl_cod	0.105	0.013	0.001
Hb>10 g/dl_cod	0.035	0.021	0.194
CIRS_SCORE ≥4	0.495	0.029	0.535

Test score: MUST, MMSE, Barthel Index; biomarkers laboratory Anemia severity: Hb>6,9 g/dl, Hb>10 g/dl; comorbidity: CIRS_SCORE ≥4.

transfusion threshold above 90 g/L: the poor tolerance of anemia (*p*=0.001) and clinical situations at risk for poor tolerance of anemia (*p*=0.03) [29]. The most frequent symptoms of poor tolerance of anemia were cardiovascular symptoms and acute neuropsychiatric symptoms that could be considered as specific criteria for red cell transfusion in the elderly [30].

Discussion

The results confirm that anemia is prevalent and often multifactorial in the elderly: 55.9% of study participants were anemic and 65.4% of anemic patients had two to four concomitant potential causes of anemia. Anemia increases the risk of mortality and morbidity and adversely affects quality of life, self-sufficiency, and cognitive function [31].

This study showed that low Hb levels were associated with worse outcomes in several CGA tests and thus with multidimensional loss of function, with MLF still significant after adjustment for comorbidity. Against the backdrop of an aging society, these findings highlight the relevance of low Hb level in identifying elderly patients at risk for adverse outcomes during nursing home stays [32]. This study also shows that anemia is associated with a higher total CIRS-G score, with comorbidities adversely impacting anemic prevalence and outcomes [33]. The association with the CIRS-G score supports the usefulness of this score as an additional marker for frailty, whose pathogenic factors include several causes of anemia (mainly nutritional deficiencies and chronic diseases) [34].

Protein malnutrition is usually not considered to be a cause of anemia, and its role is difficult to evaluate because malnutrition is often associated with vitamin deficiencies and comorbidities that can contribute to anemia [35].

However, some proteins are essential for blood cell production, so protein deficiency may indeed contribute directly to the development of anemia [36]. The comprehensive nature of the laboratory screen performed in all of this study's anemic patients may help to explain this difference (Malnutrition *vs* Comorbidity related anemia).

Complementing indicators of anemic risk, effective treatment of anemia can result in lower mortality and morbidity rates in the elderly. However, few studies have focused specifically on anemia in the elderly or on its underlying causes. In this study, severe renal impairment was found in nearly one-third of patients and was a possible cause of anemia in almost half of the anemic patients. Although advanced age is associated with a poor response of the erythropoietic system to stress, this itself does not cause anemia [37]. It is suggested that cytokines may inhibit erythropoiesis and thus lead to inflammatory anemia, but the precise causal mechanisms are not completely understood [38]. It is clear, however, that renal failure must be looked for routinely as a cause of anemia in the elderly, both because renal failure is common after 80 years of age and because recombinant erythropoietin is a simple and effective, albeit underused, treatment [39].

Strong aspects of this study include the training for data collectors, the overall size of the study sample, the use of an explicit conceptual framework on PBM, and the use of international, standardized tools to evaluate and describe patient characteristics.

The subgroups' sample sizes, convenience sampling and the difficulty of generalization beyond the study population represent some limitations of the research.

Conclusion

Multimorbidity is naturally prevalent in nursing home settings, particularly for those patients in whom severe renal and cardiovascular diseases are present. Therefore, the high burden of comorbidities must be taken into account when considering the high anemia prevalence in this study population. Nevertheless, this study's results could be applied to better understand the role of PBM with CBA and biomarkers recorded in geriatric practice, transfusion thresholds, and target hemoglobin levels after transfusion. The identification of risk factors and screening markers for functional decline related to geriatric anemia that have been demonstrated in this study might have important implications for the identification of frail older people at risk for adverse outcomes [40].

With regard to functionality, in this study, Hb concentration and anemia prevalence were all significantly associated with CGA test outcomes. It is possible that the association between anemia and MLF might result from a direct independent deteriorating effect of anemia on performance across various functional domains. With regard to cognitive function, previous studies have found anemia to be associated with cognitive impairment in specific domains as well as related to dementia and delirium [41]. In this study only MMSE results were significantly related to anemia, whereas group differences in CDT scores were not significant. There are many possible mechanisms by which anemia can contribute to cognitive impairment, ranging from a synergistic direct vascular effect with cardiovascular diseases, to reduced neuroprotection due to Erythropoietin (EPO) deficiency in the elderly, to an indirect effect on cognitive function by negatively influencing physical fitness and cardiac function [42].

Questions regarding the influence of low Hb levels on distinct cognitive domains exceed the objectives of this study and should be addressed by future research. Future interventional studies could be conducted to evaluate the clinical relevance of specific geriatric criteria in transfusion indications that seem related to comorbidities. Studies are also needed to define optimal hemoglobin levels and to confirm the causal link between anemia and laboratory test abnormalities [43]. Finally, further studies could evaluate therapeutic interventions for anemia in the elderly, including cost effective therapeutic services aligning with multidisciplinary recommendations for pharmacy benefit management in nursing homes.

A parallel, significant restriction of healthcare costs is also predicted. Indeed, the great interest currently been shown in PBM, not only in North America, has firm financial roots. In this respect, according to a recent report from a Chicago-based healthcare analysis company, the "Huron Healthcare Consulting Group", PBM is one of the ten "overlooked opportunities" that could enable healthcare systems to improve the quality of their performance considerably while reducing the cost of blood use by 10-20%, precisely through better management of this resource [44].

In this context, the multidisciplinary recommendations for the implementation of PBM in Nursing Homesare a useful instrument

for healthcare staff and management in public and private structures, supporting the provision of cost-effective therapeutic services [45].

References

1. Kacker S, Frick KD, Tobian AA. The costs of transfusion: economic evaluations in transfusion medicine, Part 1. Transfusion. 2013; 53: 1383-1385.

2. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014; 89(1): 88-96.

3. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000; 51: 245-270.

4. Van Houwelingen AH, den Elzen WP, Mooijaart SP, Heijmans M, Blom JW, de Craen AJ, et al. Predictive value of a profile of routine blood measurements on mortality in older persons in the general population: the Leiden 85-plus Study. PloS One. 2013; 8.

5. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg. 2013; 116: 15-34.

6. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist. 2011; 16: 3-11.

7. Gallagher T, Darby S, Vodanovich M, Campbell L, Tovey J. Patient blood management nurse vs transfusion nurse: is it time to merge? Br J Nurs. 2015; 24: 492-495.

8. De Leon EM, Szallasi A. "Transfusion indication RBC (PBM-02)": gap analysis of a Joint Commission Patient Blood Management Performance Measure at a community hospital. Blood Transfus. 2014; 12: 187-90.

9. British Committee for Standards in Haematology, Transfusion Task Force. Boulton FE, James V. Guidelines for policies on alternatives to allogeneic blood transfusion 1. Predeposit autologous blood donation and transfusion. Transfus Med. 2007; 17: 354-365.

10. Sixty-third World Health Assembly. WHA63.12. Availability, safety and quality of blood products. 2010.

11. Spahn DR, Moch H, Hoffmann A, Isbister JP. Patient blood management: the pragmatic solution for problems with blood transfusion. Anesthesiology. 2008; 109: 951-953.

12. Bailey RA, Reardon G, Wasserman MR, McKenzie RS, Hord RS. Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the minimum data set in long-term care residents. Health Qual Life Outcomes. 2012; 10: 129.

13. Collins C, Wade DT, Davies S, Horne V. The Barthel ADL index: a reliability study. Int Disabil Stud. 1998; 10: 61-63.

14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental-state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.

15. Connor DJ, Seward JD, Bauer JA, Golden KS, Salmon DP. Performance of three clock scoring systems across different ranges of dementia severity. Alzheimer Dis Assoc Disord. 2005; 19: 119-127.

16. Den Elzen WP, Willems JM, Westentorp RG, de Craen AJ, Assendelft WJ, Gusselkloo J. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus study. CMAJ 2009; 181: 151-157.

17. Beghe C, Ershler WB, Wilson A. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. AmJMed. 2004; 116: 3-9.

18. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation. 2003; 107: 223-225.

19. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kid Dis. 2000; 35: 250-256.

20. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995; 43: 130-137.

21. Artz AS. Anemia and the frail elderly. Semin Hematol. 2008; 45: 621-626.

22. Chaves PH. Functional outcomes of anemia in older adults. Semin Hematol. 2008; 45: 255-260.

23. Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Curr Opin Hematol. 2005; 12: 123-128.

24. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006; 107: 3841-3846.

25. Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003; 51: 451-458.

26. Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "health and anemia" study. PLoS One. 2008; 3(4): e1920.

27. Wallis JP. Disentangling anaemia and transfusion. Transfusion. 2011; 51: 8-10.

28. Landi F, Russo A, Danese P, Liperoti R, Barillaro C, Bernabei R, et al. Anemia status, hemoglobin concentrations, and mortality in nursing home older residents. J Am Med Dir Assoc. 2007; 8: 322-327.

29. Van Iperen CE, van de Wiel A, Marx JJ. Acute event-related anaemia. Br J Haematol. 2001; 115: 739-743.

30. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011-1023.

31. Endres HG, Wedding U, Pittrow D, Thiem U, Trampisch HJ, Diehm C. Prevalence of anemia in elderly patients in primary care: impact on 5-year mortality risk and differences between men and women. Curr Med Res Opin. 2009; 25: 1143-1158.

32. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol. 2008; 45: 250-254.

33. Robinson B, Artz AS, Culleton B, Critchlow C, Sciarra A, Audhya P. Prevalence of anemia in the nursing home: contribution of chronic kidney disease. J Am Geriatr Soc. 2007; 55: 1566-1570.

34. Shander A. Anemia in the critically ill. Crit Care Clin. 2004; 20: 159-178.

35. Serraj K, Federici L, Kaltenbach G, Andres E. Nutritional anemias in elderly patients. Presse Med 2008; 37: 1319-1326.

36. Nilsson-Elhe H, Jagenburg R, Landahl S, Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol. 2000; 65: 297-305.

37. Adamson JW. Renal disease and anemia in the elderly. Semin Hematol. 2008; 45: 235-241.

38. Means RT. Hepcidin and cytokines in anaemia. Hematology. 2004; 9: 357-362.

39. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev. 2006; 20: 213-226.

40. Anthes E. Evidence-based medicine: save blood, save lives. Nature. 2015; 520: 24-26.

41. Hong CH, Falvey C, Harris TB, Simonsick EM, Satterfield S, Ferrucci L. (2013) Anemia and risk of dementia in older adults: findings from the Health ABC study. Neurology. 2013; 81: 528-533.

42. Ershler WB. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc. 2003; 51: 18-21.

43. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anemia in older persons: systematic review. BMC Geriatr. 2008; 8: 1.

44. Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am. 2014; 96: 624-630.

45. Spahn DR, Moch H, Hoffmann A, Isbister JP. Patient blood management: the pragmatic solution for problems with blood transfusion. Anesthesiology. 2008; 109: 951-953.